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Abstract
Idiopathic nephrotic syndrome (INS) is one of the most common glomerular
diseases in children and adults, and the central event is podocyte injury. INS is
a heterogeneous disease, and treatment is largely empirical and in many cases
unsuccessful, and steroids are the initial mainstay of therapy. Close to 70% of
children with INS have some response to steroids and are labelled as
steroid-‘sensitive’, and the rest as steroid-‘resistant’ (also termed focal
segmental glomerulosclerosis), and single-gene mutations underlie a large
proportion of the latter group. The burden of morbidity is enormous, both to
patients with lifelong chronic disease and to health services, particularly in
managing dialysis and transplantation. The target cell of nephrotic syndrome is
the glomerular podocyte, and podocyte biology research has exploded over the
last 15 years. Major advances in genetic and biological understanding now put
clinicians and researchers at the threshold of a major reclassification of the
disease and testing of targeted therapies both identified and novel. That
potential is based on complete genetic analysis, deep clinical phenotyping, and
the introduction of mechanism-derived biomarkers into clinical practice. INS
can now be split off into those with a single-gene defect, of which currently at
least 53 genes are known to be causative, and the others. Of the others, the
majority are likely to be immune-mediated and caused by the presence of a
still-unknown circulating factor or factors, and whether there is a third (or more)
mechanistic group or groups remains to be discovered. Treatment is therefore
now being refined towards separating out the monogenic cases to minimise
immunosuppression and further understanding how best to stratify and
appropriately direct immunosuppressive treatments within the immune group.
Therapies directed specifically towards the target cell, the podocyte, are in their
infancy but hold considerable promise for the near future.
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Introduction
The glomerulus is the filtration unit of the kidney and allows the 
passage of vast amounts of water and small solutes (180 l per day 
in an adult human) into the urinary space while preventing the 
passage of almost any protein (<30 mg/day). This highly spe-
cialised property is achieved by the glomerular filtration barrier 
(GFB), comprising endothelial cells, a unique basement membrane, 
and podocytes on the urinary side.
Damage to the GFB can come from many potential sources, 
including genetic defects (primarily affecting podocytes), 
paracrine events (for example, affecting endothelial-podocyte 
cross-talk or from adjacent mesangial cells), or systemic circu-
lating insults. The last of these can take many forms, including 
circulating immune complexes, metabolic disturbances (most 
commonly, diabetes), infections, toxins (for example, shiga toxin 
in haemolytic uraemic syndrome) and drugs.
The clinical manifestation is of oedema, low serum albumin, and 
massive proteinuria. This leads to numerous consequences, related 
to circulatory/dynamic effects, and loss of essential circulating 
proteins.
Idiopathic, or primary, nephrotic syndrome is often used to 
describe the group of patients for whom no specific cause has 
been identified, and the histology is relatively non-specific. These 
patients will usually receive immunosuppression without 
knowledge of the mechanism and be categorised according to 
response. So the challenge is to understand and categorise the 
underlying injury at a molecular level and therefore adapt treat-
ments according to the likely mechanism.
Idiopathic nephrotic syndrome current classification
Current classification of idiopathic nephrotic syndrome (INS) 
is based on observational characteristics. This can be according 
to response to steroids, which is the usual first-line response, or 
according to light microscopy patterns of injury on renal biopsy. 
The commonest biopsy finding, particularly in children, is of 
‘minimal change’ nephrotic syndrome (MCNS). This means that 
light microscopy is entirely normal, importantly not even show-
ing any signs of immune infiltration or upregulation of immune 
markers. Pathology is seen only at the level of electron micros-
copy, where effacement or flattening of podocyte foot processes is 
the characteristic finding in any patient with nephrosis. The next 
most common biopsy finding (between 10% and 20% of patients) 
is of focal segmental glomerulosclerosis (FSGS), a description of 
chronic, fibrotic damage in the glomerulus. Response to therapy 
often (but not always) correlates with these biopsy findings, in that 
most patients with MCNS will be sensitive to steroids and most 
with FSGS will be resistant. However, there are many shades 
in between these phenotypes, and patients frequently become 
relapsing, steroid-dependent, calcineurin-responsive, and so on. 
This reflects our lack of knowledge of the underlying mechanisms 
and the need for a different approach to this disease.
Genetics
The most concrete advance in establishing the underlying 
mechanistic cause of INS in recent years has been the discovery 
that a substantial proportion of patients with steroid-resistant 
nephrotic syndrome (SRNS) have a single-gene mutation causing 
their disease (Table 1). To date, at least 53 different genes have 
been implicated1, almost all causing structural or functional 
defects in the podocyte. Some mutations cause isolated kidney 
disease, others are part of a syndromic condition. Most are 
autosomal-recessive, though a few present as X-linked or 
autosomal-dominant, the latter usually presenting later in life. 
Some genes have been linked with steroid or cyclosporine sen-
sitivity, such as EMP22 or KANK genes3, though the data are 
still sporadic and need consistent verification in other pedigrees.
The incidence of genetic disease in the population varies with age, 
and over 80% of patients presenting under the age of a year have 
an identifiable mutation4,5. Overall, in childhood, the incidence 
in an unselected UK national cohort of SRNS has been reported 
as 26.5%1. The incidence in adulthood remains to be ascertained, 
and phenotype even within individual pedigrees, such as ACTN4 
mutations6, is often highly variable.
With the advent of next-generation sequencing, the ability to 
screen for genetic causes in a clinical setting, despite the ever-
increasing number of genes to be screened, has become practical, 
cost-effective and rapid7 and is changing clinical practice. Gene 
panels such as the Bristol SRNS panel (https://www.nbt.nhs.uk/
severn-pathology/pathology-services/bristol-genetics-labora-
tory-bgl) can now yield a result within 4 weeks, thus potentially 
obviating the need for a biopsy and allowing consideration of 
early withdrawal of immunosuppression if a positive result is 
found.
Circulating factor disease
Patients who screen negative for the known SRNS genes, as well 
as those with steroid-sensitive disease, fall into a category 
wherein a substantial proportion will have an immune-mediated, 
circulating factor disease (CFD). The evidence for this remains 
circumstantial, and the most compelling clinical scenario is that 
of post-transplant recurrence of disease8. This is a situation where 
patients with SRNS who eventually reach established renal failure 
are then transplanted. Between 30% and 50% of patients suffer 
from rapid (most commonly, hours or days post-transplant) recur-
rence of massive proteinuria, and biopsy of the new kidney shows 
classic foot process effacement. This is presumed to be due to a 
circulating factor, and a fascinating recent case report described 
a patient with early recurrence, whose newly transplanted 
kidney was then removed and re-transplanted into a recipient 
without SRNS, and the kidney recovered completely9. It is not 
known where the circulating factor or factors originate, but the 
fact that immunosuppression is often effective, and relapses are 
often triggered by viral infections, points to the immune system 
(Table 2). Both T cells and B cells have been implicated10; for 
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Table 1. Some of the more common genes mutated in monogenic steroid-‘resistant’ nephrotic syndrome.
Function Protein Gene Syndrome Mode of 
inheritance
Histology
Slit diaphragm 
protein
Nephrin NPHS1 Congenital nephrotic 
syndrome
AR Microcystic dilatation of 
tubules and progressive 
mesangial sclerosis
SRNS AR MPGN, MCD, FSGS
Podocin NPHS2 Congenital nephrotic 
syndrome
AR
SRNS AR FSGS
PLCE1 NPHS3 DMS AR DMS
SRNS AR FSGS
CD2AP CD2AP SRNS AD/AR FSGS
SD ion channel TRPC6 TRPC6 SRNS AD FSGS
Developmental WT1 WT1 Denys–Drash 
syndrome
AD DMS
Frasier syndrome AD FSGS
Isolated SRNS AR DMS, FSGS
Actin regulating α-Actinin 4 ACTN4 Adult-onset SRNS AD FSGS
Inverted formin 2 INF2 SRNS AD FSGS
Glomerular basement 
membrane
Laminin β2 LAMB2 Pierson syndrome AR DMS, FSGS
Others tRNA-LEU MTTL1 MELAS Maternal FSGS
Parahydroxybenzoate-
polyprenyltransferase
COQ2 CoQ10 deficiency AR Collapsing 
glomerulopathy
Prenyl diphosphate 
synthase subunit 2
PDSS2 CoQ10 deficiency/
Leigh syndrome
AR FSGS
SMARCA-like protein SMARCL1 Schimke immuno-
osseous dysplasia
AR FSGS
Lysosomal integral 
membrane protein type 2
SCARB2 Action myoclonus-
renal failure 
syndrome
AR
LIM homeobox 
transcription factor 1β
LMX1B Nail patella 
syndrome
AD FSGS
Zinc metallo-proteinase 
STE24
ZMPSTE24 Mandibuloacral 
dysplasia
AR
WD repeat-containing 
protein 73
WDR73 Galloway–Mowat 
syndrome
AR DMS, FSGS
Phosphomannomutase 2 PMM2 Congenital defects 
of glycosylation
AR Collapsing 
glomerulopathy
β-1, 4-Mannosyltransferase ALG1 Congenital defects 
of glycosylation
AR FSGS
AD, autosomal-dominant; AR, autosomal-recessive; CoQ10, coenzyme Q10; DMS, diffuse mesangial sclerosis; FSGS, focal segmental 
glomerulosclerosis; MCD, minimal change disease; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; MPGN, 
membranoproliferative glomerulonephritis; SRNS, steroid-‘resistant’ nephrotic syndrome.
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Table 2. A selection of suggested circulating factors in idiopathic nephrotic syndrome.
Postulated circulating factor Experimental or clinical evidence
Hemopexin Both recombinant and human hemopexin induced reversible proteinuria in rats32. Decreased 
serum hemopexin with increased protease activity in ‘minimal change’ nephrotic syndrome 
(MCNS) in relapse33. Induced nephrin-dependent cytoskeletal rearrangements in podocytes34
suPAR 
(soluble urokinase-type 
plasminogen activator receptor)
Activated podocyte β3 integrin, resulting in reorganisation of the actin cytoskeleton 
High levels were reported in patients with focal segmental glomerulosclerosis (FSGS) and 
post-transplant recurrence35. Clinical data were not consistently replicated in other studies36.
Tumour necrosis factor-alpha 
(TNFα)
Increased concentrations were found in culture supernatants of mitogen-stimulated peripheral 
blood mononuclear cells from patients with FSGS37. 
Four of ten children with primary FSGS exhibited remission of proteinuria in a phase I trial of a 
TNFα-neutralising antibody38.
Interleukin-13 (IL-13) Increased expression of mRNA and cytoplasmic IL-13 in CD4+/CD8+ T cells from children with 
steroid-sensitive idiopathic nephrotic syndrome39. Overexpression of IL-13 in rats induces 
MCNS-like disease40.
Galactose (inhibitor of 
circulating factor)
Binds to putative circulating factor and inhibits its activity41. A clinical trial of galactose showed 
no remission effect42.
example, anti-CD20 B cell-depleting monoclonal antibodies are 
highly effective in some patients11, and a T helper 17/regulatory 
T (Th17/Treg) cell imbalance has been described in minimal 
change disease12. Another clue to a circulating factor pathogen-
esis in steroid-sensitive nephrotic syndrome, where the biopsy 
shows minimal change, is the lack of immune cell infiltration or 
activation within the glomerulus itself.
A significant gap in our knowledge is whether there is one 
common circulating factor that causes all forms of the disease, 
or several distinct factors, or possibly a family of related factors. 
There are no indications at present, either laboratory or clinical, 
that help to resolve this question, though we have made progress 
in some areas of prediction of CFD.
Clinical biomarkers
There have been no consistent clinical cues to either whether a 
patient with nephrotic syndrome has the risk of becoming steroid-
resistant in the future or whether they will suffer recurrence post-
transplant. There are weak clinical associations with recurrence 
(for example, age at onset of disease13,14, race15, serum albumin at 
diagnosis13 or time to first dialysis/transplant13,15,16). Interestingly, 
the last two features may point to the possibility that CFD has a 
more aggressive presentation and natural course, compared with the 
monogenic or ‘other’ groups. To address the question of whether 
there are clinical features that pertain to CFD, we hypothesised 
that patients with the archetypal CFD, those with post-transplant 
recurrence, would have distinct early clinical features regard-
ing their initial response to immunosuppression. If a patient has 
initial steroid sensitivity (otherwise described as secondary ster-
oid resistance), they are likely to have an immune-mediated 
circulating factor causing their underlying disease and therefore 
high risk of recurrence. On retrospective review of 150 trans-
planted patients with SRNS, we found that 93% of patients with 
initial steroid sensitivity recurred post-transplant (odds ratio = 30, 
P <0.0001), making this by far the strongest clinical biomarker 
for recurrent disease yet found17.
Laboratory biomarkers
Over many decades, researchers have searched for the elusive 
circulating factor or factors, but there has been no consistent answer 
to date18. Clearly, if the factor were identified, this would be the 
ideal biomarker to both diagnose and monitor disease activity. 
There are other rational ways to approach biomarker discovery, 
based on the fact that circulating blood from patients with active 
disease is likely to carry the active factor and that we know the 
most likely target cell of such a factor, the podocyte. Therefore, 
an approach of stimulating human podocytes in vitro with plasma 
or serum from disease has been used by ourselves and others, and 
podocyte damage has been assayed in various ways. For example, 
we have shown that plasma exchange fluid from patients being 
treated for post-transplant recurrence causes relocalisation of 
key podocyte slit diaphragm proteins19 and abnormal signal-
ling and cell motility20. Torban et al. showed a tumour necrosis 
factor-alpha (TNFα) pathway-dependent change in podocyte 
cytoskeletal changes21 and also changes in podocyte focal adhe-
sion complexes22. The challenge is to show consistency and disease 
specificity by using these types of assays, before they can be intro-
duced into clinical practice.
Newer therapies
The mainstay of current therapy is immunosuppression, which 
is appropriate for the immune-mediated group of diseases, but 
there is very limited evidence of efficacy in monogenic disease. 
There are studies that support a direct effect of some immuno-
suppressive drugs on the podocyte23–27, though the majority of 
clinical evidence points to efficacy being achieved via effects on 
the immune system.
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Some newer therapies have been proposed on the basis of direct 
targeting of either the immune system or podocyte signalling 
pathways. The most prominent of these are the use of anti-CD20 
monoclonal antibodies28, which deplete B cells, and anti-B7-1 
monoclonal antibody therapy29. The latter has been proposed fol-
lowing the observation that in certain experimental and human 
glomerular diseases the T-cell co-stimulatory molecule B7-1 has 
been noted to be upregulated on podocytes30. This can be targeted 
by the drug abatacept and is the subject of current trials in larger 
numbers of patients.
Future stratification and personalised medicine
Our understanding of INS at the molecular, cell biology and 
genetic levels is advancing rapidly, and the information gained 
will be critical in stratification and re-categorisation of patients 
into clinically useful mechanistic categories. The advent of rapid 
second- and now third-generation sequencing technologies is 
already changing clinical practice. Exome/genome sequencing, 
side by side with powerful population sequencing databases such 
as the exome aggregation consortium (ExAC)31, means that novel 
genes will continue to be discovered, even from sporadic cases, to 
complete our knowledge of the extent of heritable disease in this 
population.
A challenge of CFD is to discover whether this is a single entity, 
or separate mechanistic diseases, and target the most appropriate 
therapies to the individual groups. For example, is relapsing 
non-progressive disease different from secondary steroid resist-
ance, which usually leads to renal failure (and recurrence post- 
transplant)?
Novel therapies based on common podocyte signalling pathways 
are already on the horizon, and the availability of large national 
patient registries currently being developed will greatly accelerate 
the ability to trial these in appropriately chosen patient groups.
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